| Active substance | pembrolizumab |
| Holder | MSD |
| Status | Running |
| Indication | in combination with platinum and fluoropyrimidine based chemotherapy as first-line treatment for patients with locally advanced unresectable or metastatic carcinoma of the esophagus or HER-2 negative gastroesophageal junction Siewert type I adenocarcinoma in adults whose tumours express PD-L1 with a CPS≥10. |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 09/08/2022 |